drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Autologous or allogeneic T cells transduced with a lentiviral vector to express a CD19-specific chimeric antigen receptor; IV infusion at 2×10^6–1×10^7 CAR-T/kg with dose escalation to define MTD; mediates MHC-independent cytotoxicity against malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous or allogeneic T cells are lentivirally engineered to express a CD19-specific chimeric antigen receptor. Upon CAR binding to CD19 on B-lineage malignant cells, the T cells are activated in an MHC-independent manner, expand, and mediate cytotoxicity via perforin/granzyme release and cytokine signaling, leading to targeted depletion of CD19+ tumor cells.
drug_name
CD19-directed CAR T cells
nct_id_drug_ref
NCT06849921